BABrenna Md Anderson

Brenna Md Anderson

*This is an algorithmically generated author record based on publicly available information.

Brenna Md Anderson has a total of 48 co-authors. Here are the top co-authors by number of shared publications:

  • Christina Raker

    Division of Kidney Disease and Hypertension, Department of Medicine, Rhode Island Hospital, Providence, Rhode Island

    7 shared publications
  • Susan Cu-Uvin

    Department of Obstetrics and Gynecology, Women & Infants' Hospital, The Warren Alpert Medical School of Brown University/Miriam Hospital, Providence, RI, USA

    7 shared publications
  • Dwight J. Rouse

    Division of Maternal Fetal Medicine, Women and Infants Hospital, Brown University, Providence, Rhode Island

    4 shared publications
  • Hector Mendez-Figueroa

    Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, Women & Infants' Hospital, The Warren Alpert Medical School of Brown University, Providence, RI, USA

    3 shared publications
  • Sharon L. Hillier

    Division of Infectious Diseases and Immunology, Department of Obstetrics, Gynecology and Reproductive Sciences, Magee-Womens Hospital of UPMC, Pittsburgh, PA, USA

    3 shared publications
  • Angela M. Caliendo

    From the *Department of Obstetrics and Gynecology, Women & Infants Hospital/Alpert Medical School at Brown University, Providence, RI; †Clinical HIV Research Unit, Faculty of Health Science Center, Department of Medicine, University of Witwatersrand, Johannesburg, South Africa; ‡Right to Care, Johannesburg, South Africa; §Department of Biostatistics, Brown University, Providence, RI; ¶Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA

    2 shared publications

Latest Publications

  • Communicable Diseases

    by Erica J. Hardy, Brenna L. Anderson

    Globally, infectious diseases often disproportionately affect women, and have implications for the health of future generations. The human immunodeficiency virus (HIV), tuberculosis, malaria, and schistosomiasis are four such pathogens. Infection with these organisms has a broad impact on maternal child health in many areas of the developing world, and global initiatives to control these diseases will significantly improve the health of generations to come.

  • Lactic Acid Measurement to Identify Risk of Morbidity from Sepsis in Pregnancy

    by Tariq N. Ali, Vrishali Lopes, Dwight J. Rouse, Brenna L. Anderson, Catherine M. Albright

    Objective This study aims to assess the risk of morbidity associated with maternal lactic acid concentration in women with possible sepsis in pregnancy. Study Design Retrospective cohort of pregnant and postpartum patients with signs of sepsis. Morbidity outcomes were compared by lactic acid concentration. Linear regression was used to evaluate the association between lactic acid and adverse outcomes. Results Out of the 850 women included, 159 had lactic acid measured. Patients with lactic acid measured had higher morbidity: positive blood cultures (16.8 vs. 5.5%, p = 0.04), admission to the intensive care unit (5 vs. 0.1%, p < 0.01) or acute monitoring unit (17.2 vs. 0.9%, p < 0.01), longer hospital stay (median 3 vs. 2 days, p < 0.01), and preterm delivery (18.3 vs. 10.9%, p = 0.05). The mean lactic concentration was higher in patients admitted to the intensive care (2.6 vs. 1.6 mmol/L, p = 0.04) and telemetry unit (2.0 vs. 1.6, p = 0.03), and in those with positive blood cultures (2.2 vs. 1.6, p < 0.01). Lactic acid was positively associated with intensive care or telemetry unit admission, adjusted odds ratio per 1 mmol/L increase in lactic acid 2.34 (95% confidence interval, 1.33–4.12). Conclusion Elevated lactic acid in pregnancy is associated with adverse maternal outcomes from presumed sepsis. In this cohort, lactic acid measurement was a marker of more severe infection. Poster presented at: (no. 571) 34th Annual Meeting of the Society for Maternal Fetal Medicine; February 3–8, 2014; New Orleans, LA.


  • Ethnic Variations in Cervical Cytokine Concentrations and Vaginal Flora During Pregnancy

    by Riana Dutt, Christina Raker, Brenna L. Anderson

    Problem: Pregnancy‐mediated changes in immunity may influence risk of HIV‐1 acquisition. This risk appears greatest among non‐Caucasian women.Method of study: Pregnant women with low risk of immune disruption were enrolled in a prospective observational cohort. Study visits occurred each trimester and postpartum. Semi‐quantitative vaginal cultures and concentrations of cervical cytokines were compared between Caucasian and non‐Caucasian women.Results: In the second trimester, non‐Caucasian women were more likely to be colonized with Gardnerella vaginalis (62% versus 25%, P = 0.02) and non‐pigmented anaerobic gram‐negative rods (43% versus 8%, P = 0.01). Mycoplasma hominis was more frequently isolated in non‐Caucasian women throughout the second (29% versus 4%, P = 0.03) and third trimesters (35% versus 6%, P = 0.04). Non‐Caucasian women had higher median interleukin (IL)‐10 concentrations throughout the second (128 pg/mL versus 7 pg/mL, P = 0.05) and third trimesters (224 pg/mL versus 7 pg/mL, P = 0.05).Conclusion: Non‐Caucasian women experienced a greater diversity of microorganisms and increased IL‐10 in the second and third trimesters.


  • Pregnancy-induced changes in immune protection of the genital tract: defining normal

    by Brenna L. Anderson, Hector Mendez-Figueroa, Joshua D. Dahlke, Christina Raker, Sharon L. Hillier, Susan Cu-Uvin


  • Open Access

    Pregnancy with a Severe Hemoglobinopathy: Unintended Consequences of Transfusions

    by David Kim, Hector Mendez-Figueroa, Brenna L. Anderson

    We report a case of a pregnant woman with a complex hemoglobinopathy who developed a symptomatic anemia at 28 weeks of gestation and was treated with multiple transfusions of type-specific packed red blood cells. Shortly thereafter, she developed a fever and joint pains, along with laboratory values consistent with hemolysis. Timing suggested a delayed transfusion reaction. An extensive evaluation including red blood cell antigen identification and cross-reaction failed to reveal the cause for her hemolysis. Despite her critically low hemoglobin levels, her transfusions were withheld in an attempt to allow the patient to recover conservatively. With this strategy, her hemoglobin remained below her baseline, but her symptoms began to improve. Her laboratory values normalized, and hemolysis was no longer evident. Three weeks later, her hemoglobin levels returned back to her baseline without additional intervention. She went on to deliver a full-term male infant.


  • Effect of Trichomoniasis Therapy on Genital HIV Viral Burden Among African Women

    by Brenna L. Md Anderson, Cynthia Firnhaber, Tao Liu, Avril Msc Swarts, Maureen Phc Siminya, Jessica Ms Ingersoll, Angela M. Caliendo, Susan Cu-Uvin

    Background: Our objective was to test the hypothesis that treatment for trichomoniasis among HIV-infected women not taking antiretrovirals in South Africa would be associated with decreased HIV genital shedding. Methods: HIV-infected women presenting for routine HIV care were screened for trichomoniasis using self-collected vaginal swabs with a rapid point-of-care immunochromatographic antigen test. Women testing positive were offered enrollment into a prospective cohort study, if they had documented HIV infection, were aged 18 to 50 years, and were not receiving antiretroviral therapy. Recent use of postexposure prophylaxis or antibiotic therapy, active genital ulcers, or systemic illness were exclusion criteria. Cervical swabs were collected for gonococcal and chlamydial testing, and those testing positive were excluded. Women were treated with directly observed oral therapy with 2 g of oral metronidazole. A follow-up visit was scheduled 1 month after therapy, and partner letters were provided. Paired cervical wicks and plasma were collected for viral load measurement. Results: In all, 557 women were screened. Sixty tested positive for trichomoniasis, 10 subsequently met exclusion criteria, and 4 were lost to follow-up. Of 46 women evaluated at follow-up, 37 (80.4%) were cured. Plasma viral load was not significantly different after therapy (P = 0.93). Genital tract viral load decreased by 0.5 log10 (P < 0.01). The mean genital tract viral load (log10) decreased from 4.66 (P < 0.01) after therapy. Conclusions: Screening and treatment of vaginal trichomoniasis decrease genital shedding of HIV among South African women not receiving antiretrovirals at 1 month after therapy.


  • Open Access

    Letter to the Editor

    by Brenna L. Anderson, Dwight J. Rouse

    To the Editor—We read with concern the editorial of Dr Stuart Adler entitled “Primary Maternal CMV Infection During Pregnancy: Do We Have a Treatment Option?” [1]. Although we agree with Adler that cytomegalovirus (CMV) hyperimmune globulin shows promise for prevention of congenital CMV infection among mothers with primary CMV infection, his review of the literature focuses, inappropriately, on data from nonrandomized studies and therefore gives a biased view of our state of knowledge. The only randomized trial of CMV hyperimmune globulin for the prevention of congenital CMV infection was, in fact, negative, with a 44% congenital infection rate in the placebo group and a 30% rate in the immune globulin group (P = .13) (Revello, unpublished data). The editorial failed to mention that the Maternal Fetal Medicine Units (MFMU) Network of the Eunice Shriver Kennedy National Institute of Child Health and Human Development has embarked on a definitive trial of this issue (“A Randomized Trial to Prevent Congenital Cytomegalovirus Infection,” ClinicalTrials.gov NCT01376778). Cytomegalovirus hyperimmune globulin is very expensive and not without risk. Before its use is endorsed or advocated for the prevention of congenital CMV infection, we should know that it is effective and safe. At present, we don't know either of these things. The practice of obstetrics has been too long plagued by the adoption of promising but unproved interventions, many of which, once properly evaluated, were proved ineffective or even harmful. Cytomegalovirus hyperimmune globulin is promising but not proved. Thus we urge clinicians to forgo this therapy until adequate randomized trial data show efficacy and safety.


  • In vitro anti-HIV-1 activity in cervicovaginal secretions from pregnant and nonpregnant women

    by Brenna L. Anderson, Mimi Ghosh, Christina Raker, John Fahey, Yan Song, Dwight J. Rouse, Charles R. Wira, Susan Cu-Uvin


  • First-Trimester Pyelonephritis Is Associated with Later Initiation of Prenatal Care: A Retrospective Cohort Analysis

    by Mollie A. McDonnold, Alexander M. Friedman, Christina A. Raker, Brenna L. Anderson

    We sought to determine the morbidity, frequency, and demographics of pregnant patients with pyelonephritis not yet receiving prenatal care compared with patients with prenatal care. We performed a retrospective cohort analysis of 254 consecutive admissions for pyelonephritis from January 2004 to June 2007 at a single tertiary hospital comparing patients with prenatal care versus patients with no prenatal care. The sample size was adequate to detect a 1-day difference in length of admission between the two groups with an α of 0.05 and 80% power. Categorical variables were compared by Fisher exact test, and continuous variables were compared by the Wilcoxon rank sum or Kruskal-Wallis test. Of the 254 cases, 35 (13.8%) occurred in women who had not established prenatal care. There was no difference in the primary outcome of hospital length of stay. Overall, 29 cases (11.4%) occurred prior to 12 weeks and of these, significantly more patients presented having not established prenatal care (18 versus 11, p < 0.0001). The majority of cases of pyelonephritis that occur prior to 12 weeks are among women with no prenatal care. Although the U.S. Preventative Services Task Force guidelines advise screening urine culture at 12 to 16 weeks, these findings support initiating screening at an earlier gestational age. Presented at the 36th Annual Scientific Meeting, Infectious Disease Society for Obstetrics and Gynecology, Montreal, Quebec, CA. August 7, 2009.